Flexion Therapeutics (FLXN) Upgraded at BidaskClub

BidaskClub upgraded shares of Flexion Therapeutics (NASDAQ:FLXN) from a sell rating to a hold rating in a report released on Saturday morning.

A number of other equities research analysts also recently weighed in on FLXN. Zacks Investment Research raised Flexion Therapeutics from a sell rating to a hold rating in a research note on Friday, May 11th. ValuEngine raised Flexion Therapeutics from a hold rating to a buy rating in a research note on Friday, April 27th. Wells Fargo reaffirmed a buy rating on shares of Flexion Therapeutics in a research note on Saturday, May 5th. BMO Capital Markets reaffirmed an outperform rating and set a $36.00 price target (down from $37.00) on shares of Flexion Therapeutics in a research note on Friday, March 9th. Finally, Berenberg Bank began coverage on Flexion Therapeutics in a research note on Thursday, February 1st. They set a buy rating and a $42.00 price target for the company. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The stock currently has an average rating of Buy and an average price target of $99.00.

Shares of Flexion Therapeutics opened at $27.49 on Friday, according to MarketBeat. Flexion Therapeutics has a one year low of $16.51 and a one year high of $32.25. The stock has a market cap of $1.04 billion, a price-to-earnings ratio of -6.61 and a beta of 0.82. The company has a debt-to-equity ratio of 0.67, a current ratio of 15.57 and a quick ratio of 15.47.

Flexion Therapeutics (NASDAQ:FLXN) last announced its quarterly earnings data on Tuesday, May 8th. The specialty pharmaceutical company reported ($1.10) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.33) by $0.23. The business had revenue of $2.19 million for the quarter, compared to analyst estimates of $1.99 million. equities analysts expect that Flexion Therapeutics will post -4.74 EPS for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of FLXN. Advisory Services Network LLC bought a new position in shares of Flexion Therapeutics in the 4th quarter valued at approximately $108,000. Redmile Group LLC bought a new position in shares of Flexion Therapeutics in the 1st quarter valued at approximately $223,000. Teacher Retirement System of Texas bought a new position in shares of Flexion Therapeutics in the 4th quarter valued at approximately $245,000. Stifel Financial Corp bought a new position in shares of Flexion Therapeutics in the 1st quarter valued at approximately $293,000. Finally, Eaton Vance Management raised its stake in shares of Flexion Therapeutics by 37.2% in the 4th quarter. Eaton Vance Management now owns 12,900 shares of the specialty pharmaceutical company’s stock valued at $323,000 after acquiring an additional 3,500 shares in the last quarter. 97.05% of the stock is owned by institutional investors.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee.

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply